• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ann Med Surg (Lond) . The association of posterior reversible encephalopathy syndrome with COVID-19: A systematic review

tetano

Editor, Senior Moderator
Ann Med Surg (Lond)


. 2021 Dec;72:103080.
doi: 10.1016/j.amsu.2021.103080. Epub 2021 Nov 20.
The association of posterior reversible encephalopathy syndrome with COVID-19: A systematic review


Sadaf Iftikhar[SUP] 1 [/SUP], Aqeeb Ur Rehman[SUP] 2 [/SUP], Muhammad Zain Ameer[SUP] 2 [/SUP], Ahmad Nawaz[SUP] 2 [/SUP], Muhammad Aemaz Ur Rehman[SUP] 1 [/SUP], Hareem Farooq[SUP] 1 [/SUP], Abyaz Asmar[SUP] 1 [/SUP], Muhammad Ebaad Ur Rehman[SUP] 3 [/SUP]



Affiliations

Abstract

The rise in Coronavirus disease 2019 (COVID-19) cases is revealing its unique neurological manifestations. In light of the emerging evidence, a possible association with Posterior Reversible Encephalopathy Syndrome (PRES) is being consistently reported. We conducted a systematic literature search on four databases namely Pubmed/MEDLINE, Cochrane, Google Scholar, and Science Direct. After rigorous screening as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a total of 34 articles describing 56 cases were selected as a part of this review. The mean age of the patients was 56.6 ± 15.3 years. The most common clinical presentation of PRES was altered mental status (58.9%) followed by seizures (46.4%) and visual disturbances (23.2%) while hypertension and diabetes mellitus were the most commonly reported comorbidities. 91.1% of the cases reported Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) findings suggestive of PRES in the brain. Symptomatic management was employed in most of the cases to control seizures and blood pressure, and 44 patients (78.5%) fully or partially recovered. The most likely underlying mechanism involves COVID-19 mediated cytokine storm syndrome that leads to endothelial damage and increased permeability of the cerebral vessels, thus causing the characteristic edema of PRES. High neuronal and glial cell expression of Angiotensin Converting Enzyme-2 (ACE-2) receptors also suggests the possibility of direct viral damage. Since timely diagnosis and treatment reports a good prognosis, it is vital for physicians and neurologists to be well-versed with this association.

Keywords: COVID-19; Cerebral edema; PRES; Posterior leukoencephalopathy syndrome; Posterior reversible encephalopathy syndrome; SARS-CoV-2.
 
Back
Top Bottom